Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401089 | PMC |
| http://dx.doi.org/10.26502/acmcr.96550511 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology, Real-World Treatment, and Economic Burden of Waldenström Macroglobulinemia: A Comprehensive Analysis Based on Anonymized Claims Data Between 2010 and 2022.
Value Health Reg Issues
September 2025
Department of Hematology and Medical Oncology, University Medical School Mainz, Mainz, Germany.
Objectives: This study aimed to provide evidence on the epidemiology, real-world treatment patterns, overall survival, and economic burden of Waldenström macroglobulinemia (WM).
Methods: A retrospective analysis of an anonymized large German claims database from January 1, 2010, to June 30, 2022, identified incident WM cases based on a 12-month diagnosis-free period before the first confirmed WM diagnosis (ICD-10-GM code C88.0).
Case Report: Two cases of primary pulmonary endobronchial extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue localized in the trachea and bronchus.
Front Oncol
August 2025
Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Background: Primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) localized in the trachea and bronchus is rare and diagnostically challenging due to nonspecific clinical and radiological features.
Case Description: We present two cases of primary endobronchial MALT lymphoma incidentally diagnosed via bronchoscopy. We assessed the characteristic bronchoscopic finding of endobronchial MALT lymphoma, radiological examinations and overall treatment strategies.
Functional Outcomes and Quality of Life in Patients Managed With Organ Preservation Following Total Neoadjuvant Therapy for Rectal Cancer-A Historical Cohort Study.
ANZ J Surg
September 2025
Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Aim: Total neoadjuvant therapy (TNT) for locally advanced rectal cancer improves oncological outcomes and organ preservation rates, but the impact on patient quality of life (QoL) is not known. This cohort study compares the quality of life (QoL) of post-TNT watch-and-wait (W&W) patients to a historical cohort of patients that underwent standard care.
Method: Patients managed with a W&W approach following a personalised TNT (pTNT W&W group) were compared with historical group patients who had undergone standard treatment but who would have been eligible for pTNT under our current protocol (STD group).
Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II).
Med
August 2025
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China; State Key Laboratory of Molecular Oncology and Department of Radiation Onc
Background: The therapeutic efficacy and mode of combining immunotherapy with neoadjuvant chemoradiotherapy in proficient mismatch repair (pMMR)/microsatellite stable (MSS) locally advanced rectal cancer (LARC) remain uncertain.
Methods: In this multicenter, randomized, seamless phase 2/3 trial (ClinicalTrials.gov: NCT05484024), eligible participants were randomly assigned (1:1) to receive short-course radiotherapy (SCRT) (5 Gy × 5), followed by 4 cycles of capecitabine and oxaliplatin or 6 cycles of leucovorin, oxaliplatin, and fluorouracil, with (iTNT group) or without (total neoadjuvant therapy [TNT] group) 4 cycles of sintilimab.
Optimal Timing for Rectal Cancer Surgery After Total Neoadjuvant Therapy: When Does Surgery Get Really Challenging?
Dis Colon Rectum
August 2025
Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.
Background: Total neoadjuvant therapy is increasingly utilized for locally advanced rectal cancer. However, the optimal interval between total neoadjuvant therapy and surgery remains unclear. Existing trials report intervals ranging from 2-4 weeks to 11-18 weeks, and many surgeons believe surgery becomes more difficult after a certain point, but the exact timing and its impact on complications are unknown.
View Article and Find Full Text PDF